Korean ultrasound vendor Medison America (Hall A, #1345) has undergone a major expansion campaign since last year's conference. The Pleasanton, CA, company aspires to break out of its niche in low-end ultrasound with a series of new product introductions
Korean ultrasound vendor Medison America (Hall A, #1345) has undergone a major expansion campaign since last year's conference. The Pleasanton, CA, company aspires to break out of its niche in low-end ultrasound with a series of new product introductions at this year's meeting.
The key to Medison's growth plan is Voluson 530D, an upgraded version of the Combison 530 3-D ultrasound scanner that Medison acquired with its purchase of Kretztechnik in 1996. Medison has added an all-new 128-channel digital beamformer that uses application-specific integrated circuits (ASICs), according to Peter Klein, president and CEO of Medison America. Medison plans to market Voluson 530D as a high-end ultrasound scanner that can also do 3-D imaging, rather than as a dedicated 3-D system, Klein said.
In conventional 2-D ultrasound, Medison also has two new product introductions, both of which are based on digital ultrasound technology. SonoAce 6000 is a lower mid-range system targeted at ob/gyn and surgical applications that will sell for just under $40,000. SonoAce 8800 is a work-in-progress color Doppler scanner with a 64-channel beamformer that will sell for about $80,000. SonoAce 6000 began selling in August, while SonoAce 8800 requires FDA clearance.
Medison also has designs on the MRI market and introduced the 1-tesla Magnum scanner at last year's meeting. This year, the company will feature the addition of fast spin-echo and 3-D gradient-echo sequences for the investigational scanner. Images acquired with the company's new 3-tesla whole-body scanner in South Korea will be displayed.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
CT Study Links Pleural Effusion and Higher 30-Day Mortality Rates in Patients with COVID-19
October 1st 2024In a multicenter study of over 1,100 patients with COVID-19, pleural effusion was detected on CT scans in nearly a third of patients, who also had significantly higher ICU admission and 30-day mortality rates.